As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a provision that could keep certain rare disease drugs from being subject to ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

If we don’t incentivize continued investments in drug research and development, we’ll lose out on new therapies that don’t ...

Drug development is a decade-long, costly process replete with failures. If we don’t incentivize investments in research and ...

Democrats aren't rushing to play ball with Republicans on a bipartisan health care package after passage of the president's ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Prescription drugs account for 15% of health care costs. Yet, they’re our best defense against the chronic diseases that ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

President Donald Trump’s “big, beautiful bill,” which he signed into law earlier this month, includes major wins for business ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...